Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Carcinoma, Non-Small-Cell Lung 6Glioblastoma 4Neoplasms 3Lymphoma 3Prostatic Neoplasms 2Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Glioma 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Lymphoid 1Gliosarcoma 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Rituximab 205Cyclophosphamide 178Peripheral Blood Stem Cell Transplantation 93Etoposide 91fludarabine phosphate 86Filgrastim 81Melphalan 62Vincristine 60Mycophenolic Acid 58Busulfan 58Whole-Body Irradiation 57Cytarabine 51Radiotherapy 49Doxorubicin 49Cyclosporine 49Tacrolimus 48Granulocyte Colony-Stimulating Factor 48Prednisone 46fludarabine 45Bendamustine Hydrochloride 45Methotrexate 44Carmustine 36Antilymphocyte Serum 34Dexamethasone 32Bortezomib 29Gemcitabine 27ibritumomab tiuxetan 25Methylprednisolone 23sargramostim 22Stem Cell Transplantation 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, Non-Hodgkin × enzastaurin × Clear all
NCT00042666 2020-08-10

A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.

Eli Lilly and Company

Phase 2 Completed
55 enrolled 13 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT00332202 2018-09-10

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Eli Lilly and Company

Phase 3 Completed
758 enrolled 20 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡